Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 2,019 Shares

Key Points

• Michael Burkes Brophy, CFO of Natera, Inc., sold 2,019 shares of the company's stock at an average price of $139.81, totaling approximately $282,276, which reduced his ownership by 2.86%.
• Natera's recent quarterly earnings report showed a 36.5% year-over-year increase in revenue, totaling $501.83 million, surpassing analysts' expectations.
• Analysts have mixed views on Natera, with ratings ranging from a "sell" to a "strong-buy", and an average price target of approximately $183.76.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 2,019 shares of the stock in a transaction on Monday, July 28th. The shares were sold at an average price of $139.81, for a total value of $282,276.39. Following the transaction, the chief financial officer directly owned 68,475 shares of the company's stock, valued at approximately $9,573,489.75. This trade represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, July 29th, Michael Burkes Brophy sold 3,045 shares of Natera stock. The stock was sold at an average price of $137.40, for a total value of $418,383.00.
• On Tuesday, July 22nd, Michael Burkes Brophy sold 920 shares of Natera stock. The shares were sold at an average price of $139.58, for a total value of $128,413.60.
• On Thursday, July 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The stock was sold at an average price of $139.50, for a total transaction of $105,322.50.
• On Wednesday, July 23rd, Michael Burkes Brophy sold 495 shares of Natera stock. The shares were sold at an average price of $141.28, for a total value of $69,933.60.
• On Monday, July 21st, Michael Burkes Brophy sold 602 shares of Natera stock. The shares were sold at an average price of $139.29, for a total transaction of $83,852.58.

Natera Trading Up 0.7%

NTRA traded up $0.92 during trading hours on Friday, hitting $134.58. The company's stock had a trading volume of 1,165,817 shares, compared to its average volume of 1,493,227. The stock has a market cap of $18.38 billion, a price-to-earnings ratio of -91.55 and a beta of 1.73. The business's 50-day moving average price is $157.54 and its 200-day moving average price is $156.09. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The company's revenue for the quarter was up 36.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.56) earnings per share. On average, analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Hedge Funds Weigh In On Natera

A number of large investors have recently bought and sold shares of NTRA. LRI Investments LLC bought a new stake in Natera during the fourth quarter valued at about $29,000. Bank of Jackson Hole Trust bought a new position in shares of Natera during the 1st quarter worth approximately $29,000. Rakuten Securities Inc. lifted its position in Natera by 117.8% during the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after acquiring an additional 119 shares during the last quarter. ORG Partners LLC acquired a new stake in Natera in the first quarter valued at approximately $32,000. Finally, TCTC Holdings LLC grew its holdings in Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock worth $33,000 after purchasing an additional 124 shares during the last quarter. Institutional investors own 99.90% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on NTRA. Evercore ISI assumed coverage on Natera in a research note on Monday. They issued an "outperform" rating and a $170.00 target price on the stock. UBS Group upped their price target on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. Wall Street Zen cut Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. Barclays boosted their target price on Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Finally, Piper Sandler upped their price objective on Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $183.76.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.